Edition:
United States

Aveo Pharmaceuticals Inc (AVEO.O)

AVEO.O on Nasdaq

0.62USD
7 Dec 2016
Change (% chg)

-- (--)
Prev Close
$0.62
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
211,927
52-wk High
$1.42
52-wk Low
$0.56

Latest Key Developments (Source: Significant Developments)

Aveo initiates evaluation of Tivozanib in combination with Bristol-Myers Squibb's opdivo in advanced renal cell carcinoma
Monday, 15 Aug 2016 07:00am EDT 

Aveo : Initiates Evaluation Of Tivozanib In Combination With Bristol Myers Squibb's Opdivo® (nivolumab) in advanced renal cell carcinoma .Phase 1/2 tinivo trial to commence at institut gustave roussy in paris.  Full Article

Aveo Oncology Q2 loss per share $0.13
Thursday, 4 Aug 2016 07:35am EDT 

Aveo Pharmaceuticals Inc : Aveo oncology reports second quarter 2016 financial results and provides business update . Q2 loss per share $0.13 Further company coverage: [AVEO.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Aveo Pharmaceuticals says sale of 37.1 mln shares by stockholders
Wednesday, 15 Jun 2016 05:12pm EDT 

Aveo Pharmaceuticals Inc :Announces sale of 37.1 million shares of common stock by selling stockholders - sec filing.  Full Article

Aveo Pharmaceuticals announces dosing of first patient in Phase 3 tivo-3 study of tivozanib in renal cell carcinoma
Thursday, 26 May 2016 07:00am EDT 

Aveo Pharmaceuticals Inc : Announces dosing of first patient in pivotal Phase 3 tivo 3 study of tivozanib in renal cell carcinoma .Top line readout of study is currently projected for Q1 of 2018.  Full Article

Aveo Pharmaceuticals announces closing of private placement and amended term loan
Wednesday, 18 May 2016 07:00am EDT 

Aveo Pharmaceuticals Inc : Announces closing of private placement and amended term loan to fund pivotal Tivo 3 trial and combination PD-1 trial of tivozanib in renal cell cancer . Entered into an amendment to its 2010 loan and security agreement with Hercules Capital Inc . Pursuant to loan amendment, company borrowed an additional $5.0 million from Hercules . If specified conditions are met, Aveo may borrow an additional tranche of $5.0 million from Hercules in first half of 2017 .If specified conditions are met, repayment of principal on Aveo's loans may be deferred to begin in 2018.  Full Article

Aveo says private placement to consist of 17.6 mln units at $0.965/unit
Friday, 13 May 2016 09:00am EDT 

Aveo Pharmaceuticals Inc : Private placement will consist of 17.6 million units, at a price of $0.965 per unit . Aveo pharmaceuticals inc says expects to use proceeds from financing to fund its u.s. Pivotal phase 3 trial of tivozanib .Aveo announces $17 million private placement.  Full Article

Aveo Pharmaceuticals Q1 loss per share $0.13
Tuesday, 10 May 2016 04:01pm EDT 

Aveo Pharmaceuticals Inc : Q1 loss per share $0.13 .Says believe that its cash resources would allow company to fund its current operations into Q4 of 2017.  Full Article

Aveo Pharmaceuticals Inc to pay U.S. SEC $4 mln to settle kidney drug case - Reuters News
Tuesday, 29 Mar 2016 12:27pm EDT 

Aveo Pharmaceuticals Inc:Biotech company Aveo Pharmaceuticals Inc AVEO.O will pay $4 million to settle civil charges that it misled investors about U.S. regulators' concerns involving its drug to treat kidney cancer, the Securities and Exchange Commission said on Tuesday. - RTRS.Aveo, in settling the case, neither admitted nor denied the SEC's allegations, the agency said. The SEC's case against three former Aveo executives involving statements the company made about the drug, Tivozanib, is continuing, the agency said.  Full Article

AVEO Pharmaceuticals Inc and Eusa Pharma announce exclusive licensing agreement for tivozanib in Europe
Monday, 21 Dec 2015 06:30am EST 

AVEO Pharmaceuticals Inc:Press release - Aveo and eusa pharma announce exclusive licensing agreement for tivozanib in Europe.Says under terms , eusa pharma will pay Aveo an upfront research and development funding payment of $2.5 million.Eusa pharma to also pay Aveo up to $394 million in potential payments and milestones.A percentage of milestone and royalty payments received by Aveo are due to kyowa hakko kirin as a sublicensing fee.Eusa pharma will undertake ,fund future regulatory and commercial activities to bring tivozanib to market.Says agreement also includes a number of additional territories outside North America.Says tivozanib partnerships collectively amount to over $35 million in potential payments over the next 18 months.Plans to submit a marketing authorization application for tivozanib to the European medicines agency in Q1 2016.  Full Article

AVEO Pharmaceuticals Inc announces Chairman Tuan Ha-Ngoc steps down
Monday, 9 Nov 2015 06:15am EST 

AVEO Pharmaceuticals Inc:Says Tuan Ha-Ngoc has stepped down as Chairman and a Director of the Company's board of directors, effective November 6.Says Henri A. Termeer, Lead Outside Director of AVEO, has assumed Board leadership responsibilities.  Full Article

BRIEF-Aveo Pharmaceuticals says Eusa Pharma submits its responses to EMA day 120 list of questions

* Says its development partner, Eusa Pharma, submitted its responses to European Medicines Agency (EMA) day 120 list of questions